Biodel Announces Removal of Partial Clinical Hold for BIOD-531 and Plans for Potential Expansion of Target Patient Population

By: via Benzinga
Biodel Inc. (NASDAQ: BIOD) today announced that the United States Food and Drug Administration (FDA) has removed the partial clinical ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.